Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2014. The report details a specific share repurchase transaction executed on June 13, 2014, authorized by shareholders at the Annual General Meeting on May 7, 2014.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 95,409 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,600 pence per share; lowest price paid was 1,595 pence per share.
- Treasury Holdings (Settled): 500,172,414 shares (9.35% of total issued share capital).
- Treasury Holdings (Including Unsettled): 501,079,179 shares (10.33% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,850,709,111 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 95,409 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.33% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (500,172,414 settled) against the company's latest capitalization table.
- Confirm the calculation of voting rights (10.33%) based on the 501,079,179 shares held in Treasury including unsettled transactions.
- Check the denominator for shareholder notification thresholds, which is 4,850,709,111 shares in issue.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial statements.